Preceptis Medical

Executive Summary

Preceptis Medical is a US-based medical device company pioneering in-office ear tube placement for children with its FDA-cleared Hummingbird Tympanostomy Tube System (TTS). The device eliminates the need for general anesthesia, enabling a safer, faster, and more cost-effective procedure that can be performed in a physician's office. This innovation addresses a significant unmet need, as over 1 million tympanostomy tube insertions occur annually in the US, mostly in operating rooms with associated risks and higher costs. Preceptis has positioned itself to disrupt the standard of care by offering a solution that reduces procedure time, avoids anesthesia-related complications, and has the potential to expand access to underserved populations. With a strong IP portfolio and growing clinical evidence supporting safety and efficacy, the company is focused on commercial scaling through direct sales and strategic partnerships. While still privately held and pre-revenue from product sales, Preceptis has the opportunity to capture significant market share if it can overcome adoption barriers such as physician training and reimbursement. The company's trajectory depends on successful commercial execution and favorable policy changes, making it an attractive but early-stage investment with meaningful upside potential.

Upcoming Catalysts (preview)

• Q3 2026Publication of pivotal clinical study results in a peer-reviewed medical journal80% success
• Q2 2026Announcement of commercial partnership with a major ENT distributor or hospital network60% success
• Q4 2026Medicare or commercial payer coverage decision for in-office tympanostomy tube placement70% success